[{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Multitope Peptide-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Nebraska Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ University of Nebraska Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ University of Nebraska Medical Center"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Ministry of Health and Welfare, Taiwan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Vaxxinity \/ Ministry of Health and Welfare, Taiwan","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Ministry of Health and Welfare, Taiwan"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vaxxinity","amount2":2.7999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":2.7999999999999998,"dosageForm":"","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"United Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ United Biomedical","highestDevelopmentStatusID":"9","companyTruncated":"Vaxxinity \/ United Biomedical"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"UB-311","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ BofA Securities"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ CEPI"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-311","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-311","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-313","moa":"CGRPR","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"UB-612","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VXX-401","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"UB-312","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"UB-311","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity \/ University of Florida"}]
Find Clinical Drug Pipeline Developments & Deals by Vaxxinity
Details :
The collaboration aims to helps Vaxxinity to work on the development of UB-311, which targets toxic forms of aggregated Aβ in the brain to fight Alzheimer disaease.
Details :
The collaboration furthers Vaxxinity’s development of active immunotherapies for muscle and bone wasting, assessing effects on undisclosed proteins in vitro, in vivo, and animal models.
Details :
UB-312 is a vaccine candidate targeting pathological forms of alpha-synuclein (aSyn) for the disease-modifying treatment and prevention of Parkinson’s disease (PD) and other synucleinopathies.
Details :
VXX-401 is an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9).
Details :
UB-612 is the first multitope subunit protein/peptide-based vaccine candidate for SARS-CoV-2, designed to activate both B- and T-cell arms of the immune system directed against multiple structural viral antigens.
Details :
Preclinically, UB-313 has shown strong immunogenicity across species, inducing anti-CGRP antibodies with similar properties as approved comparator monoclonal antibodies, as well as a favorable safety and tolerability profile.
Details :
UB-612 is the first multitope subunit protein/peptide-based vaccine candidate for SARS-CoV-2, which is designed to activate both B- and T-cell arms of the immune system directed against multiple structural viral antigens.
Details :
UB-311 is a fully synthetic vaccine candidate that employs the UBITh platform technologies to target aggregated forms of beta-amyloid in the brain to treat Alzheimer’s disease.
Details :
Long Term Extension trials showed UB-311 to be well tolerated in mild-to-moderate AD patients over three years of repeat dosing, with a safety profile comparable to placebo and no cases of amyloid-related imaging abnormalities-edema (“ARIA-E”) in the...
Details :
Outlines preliminary evidence suggesting UB-312 is well tolerated and induces dose-dependent antibody production, with high titer levels detectable in cerebrospinal fluid (CSF), a key characteristic for tackling diseases of the brain.
Reset All
